文献速递前列腺癌

转移性激素敏感性前列腺癌的癌症进展模式:ECOG3805 CHAARTED试验分析

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
PubMed 文献 · Eur Urol Oncol · 2020-08-15

该研究回顾性分析ECOG3805试验中转移性激素敏感性前列腺癌患者,按进展时PSA水平(是否低于2.0 ng/mL)和进展事件类型分类。结果显示约八分之一患者在PSA低于2 ng/mL时出现临床进展,约25%患者在没有确认PSA进展的情况下发生临床进展,且此类患者总生存期更短。结论提示仅依赖PSA监测不足,应结合影像学。

要点

  • 约八分之一患者在PSA<2 ng/mL时出现临床进展。
  • 约25%患者无确认PSA进展即发生临床进展,总生存期更短。
  • 仅靠PSA监测不足,应联合影像学监测转移性前列腺癌。

核心结论

  • 在mHSPC中,PSA升高前或低PSA水平时发生临床进展较常见,且与更差的总生存期相关。

研究设计与样本

  • 对ECOG3805随机试验中所有mHSPC患者进行回顾性分析,按进展时PSA水平(<2.0 ng/mL或否)和进展事件类型分组比较。

主要发现

  • 约八分之一患者在PSA低于2 ng/mL时出现临床进展。
  • 约25%患者在没有确认PSA进展的情况下发生临床进展。
  • 无确认PSA进展而仅临床进展的患者,从随机化起的总生存期短于仅PSA进展为首发进展的患者。
  • 研究入组时患者人口学特征不能预测进展模式。

临床怎么用

  • 不应仅依赖PSA监测mHSPC治疗中的患者,应联合影像学检查以发现低PSA或无PSA变化时的临床进展。

局限性

  • 研究为回顾性、事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ECOG3805 is a randomized trial of testosterone suppression with or without docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). Deeper prostate-specific antigen (PSA) suppression is prognostic for outcome. However, the concordance of PSA rise and radiographic progression has not been examined previously in mHSPC, whereas this has been reported in metastatic castration-resistant prostate cancer. OBJECTIVE: To determine the patterns of progression by PSA and radiographic parameters in patients in ECOG3805. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective analysis of all patients in ECOG3805. Patients were classified according to the PSA level at progression (whether PSA level was below 2.0 ng/mL or not) and the type of progression event in the study (either PSA progression as defined by the study with or without clinical progression, or clinical progression alone). Baseline demographics, clinical outcomes, and patterns of progression were compared between the groups. RESULTS AND LIMITATIONS: One in eight patients had clinical progression below a PSA level of 2 ng/mL, and approximately 25% developed clinical progression in the absence of confirmed PSA progression. Overall survival from randomization was shorter in patients with clinical progression without confirmed PSA progression than in patients with PSA progression alone as the first progression. Patient demographics at study entry were not predictive of the pattern of progression. Study limitations include its retrospective and post hoc nature. CONCLUSIONS: Clinical progression prior to PSA rise or at low PSA levels is a relatively frequent phenomenon in mHSPC and is associated with poorer overall survival. Further biological and clinical studies of these patients are warranted. PATIENT SUMMARY: Reliance on prostate-specific antigen (PSA) alone is an inadequate strategy to monitor patients undergoing treatment for metastatic hormone-sensitive prostate cancer. Prostate cancer can get worse on scans even with low PSA and/or no or small changes in PSA. Imaging should be added to PSA testing to monitor patients with metastatic prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bryce AH, Chen YH, Liu G, et al. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol. 2020. PMID: 32807727. doi:10.1016/j.euo.2020.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。